FDA Poised For Decision On Controversial Alzheimer's Drug
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer's disease rather than relieve symptoms.
But it's unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.
The FDA has a Monday deadline to make a decision on what would be the first new Alzheimer's drug in nearly two decades.
Comments